To the best of our knowledge, this is the first study to report the effects of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib pharmacokinetics in patients with thyroid cancer. The gene discussed is CYP3A4; the disease is thyroid gland carcinoma.